Patient lifting shirt showing kidney area

The first and only FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC)

Who says cancer treatment has to take my kidney?
How JELMYTO worksArrow (right) icon

Results with JELMYTO

In a study, JELMYTO has been shown to effectively treat patients with low-grade UTUC.

No hospital stay required

JELMYTO is given once a week for 6 weeks as a same-day procedure.

JELMYTO Patient Brochure

The patient brochure contains important information about what to expect from treatment with JELMYTO. English and Spanish versions are available.

Ask your doctor about JELMYTO, a nonsurgical treatment for low-grade UTUC

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Please click here for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.